CoChat

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics

Open access
Mayer, Gert J., Wanner, Christoph, Weir, Matthew R., Inzucchi, Silvio E., Koitka-Weber, Audrey, Hantel, Stefan, von Eynatten, Maximilian, Zinman, Bernard, Cherney, David Z.I. · 2019 · Kidney International
Cited by 103

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

In patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease, empagliflozin (EMPA) decreased progression of chronic kidney disease (CKD), likely via a reduction in intraglomerular pressure. Due to prevalent comorbidities, such as hypertension and albuminuria, patients often receive other agents that alter intrarenal hemodynamics, including angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), calcium channel blockers (CCBs) and diuretics. Nonsteroidal anti-inflammatory drugs (NSAIDs) may also be used by some individuals. In this exploratory, non-prespecified analysis, we investigated whether the kidney benefits of EMPA are altered in individuals already using the medications in these categories. In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME®) trial, 7020 patients were essentially equally randomized to EMPA 10 mg, 25 mg or placebo added to their standard care. Differences in risk of incident or worsening nephropathy for pooled EMPA vs placebo across subgroups by baseline background medications (to which patients were not randomized) were assessed using a Cox proportional hazards model. Risk reductions in incident or worsening nephropathy with EMPA were consistent across medication subgroups, with no heterogeneity of treatment effect. As a representative example, the risk for acute renal failure was overall slightly increased in patients using ACEi/ARBs in all groups (placebo, EMPA 10 mg or EMPA 25 mg) but incidence rates were numerically lower in those assigned to EMPA. Similar patterns were observed for other medications included in this analysis. Thus, EMPA may assist to prevent CKD progression in patients with T2DM with CV disease, irrespective of common background medications that alter intrarenal hemodynamics, and without increasing acute renal adverse events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.kint.2019.02.033

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 28

  1. Zinman, 2014, Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME), Cardiovasc Diabetol, 13, 102, 10.1186/1475-2840-13-102 · DOI · Paper page
  2. Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081 · DOI · Paper page
  3. Thomson, 2012, Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat, Am J Physiol Regul Integr Comp Physiol, 302, R75, 10.1152/ajpregu.00357.2011 · DOI · Paper page
  4. Gembardt, 2014, The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension, Am J Physiol Renal Physiol, 307, F317, 10.1152/ajprenal.00145.2014 · DOI · Paper page
  5. Anderson, 1993, Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations, Am J Physiol, 265, F477
  6. Perico, 1994, Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage, Exp Nephrol, 2, 220
  7. Sochett, 2006, Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes, J Am Soc Nephrol, 17, 1703, 10.1681/ASN.2005080872 · DOI · Paper page
  8. Fabris, 1999, Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats, J Hypertens, 17, 1925, 10.1097/00004872-199917121-00023 · doi:10.1097/00004872-199917121-00023
  9. Zatz, 1986, Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension, J Clin Invest, 77, 1925, 10.1172/JCI112521 · DOI · Paper page
  10. Nasrallah, 2009, Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2(Akita) mice, Am J Nephrol, 30, 346, 10.1159/000229304 · DOI
  11. Komers, 2001, Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes, J Clin Invest, 107, 889, 10.1172/JCI10228 · DOI · Paper page
  12. Ohno, 2016, Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure, Sci Rep, 6, 27192, 10.1038/srep27192 · DOI
  13. Chagnac, 2008, Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption, Nephrol Dial Transplant, 23, 3946, 10.1093/ndt/gfn379 · DOI · Paper page
  14. Heise, 2015, Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study, Clin Ther, 37, 793, 10.1016/j.clinthera.2014.12.018 · DOI
  15. Komlosi, 2006, Unraveling the relationship between macula densa cell volume and luminal solute concentration/osmolality, Kidney Int, 70, 865, 10.1038/sj.ki.5001633 · doi:10.1038/sj.ki.5001633
  16. Peti-Peterdi, 2010, Macula densa sensing and signaling mechanisms of renin release, J Am Soc Nephrol, 21, 1093, 10.1681/ASN.2009070759 · DOI · Paper page
  17. Weber, 2016, Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study, Lancet Diabetes Endocrinol, 4, 211, 10.1016/S2213-8587(15)00417-9 · DOI · Paper page
  18. Rahman, 2016, Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome, J Hypertens, 34, 893, 10.1097/HJH.0000000000000871 · DOI · Paper page
  19. Devineni, 2014, Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants, Clin Ther, 36, 698, 10.1016/j.clinthera.2014.02.022 · DOI · Paper page
  20. Ando, 2013, L-/N-type calcium channel blockers and proteinuria, Curr Hypertens Rev, 9, 210, 10.2174/1573402110666140131155331 · doi:10.2174/1573402110666140131155331
  21. Seino, 2007, Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus: analysis after switching from cilnidipine to benidipine, Arzneimittelforschung, 57, 526
  22. Fogari, 2007, Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria, Am J Hypertens, 20, 1092, 10.1016/j.amjhyper.2007.05.012 · DOI
  23. Fujisawa, 2007, Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy, J Diabetes Complications, 21, 252, 10.1016/j.jdiacomp.2006.06.001 · DOI
  24. Cherney, 2008, Insights into the regulation of renal hemodynamic function in diabetic mellitus, Curr Diabetes Rev, 4, 280, 10.2174/157339908786241151 · DOI
  25. Cherney, 2008, The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes, Diabetes, 57, 688, 10.2337/db07-1230 · DOI · Paper page
  26. Heyman, 2017, Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media, Diabetes Care, 40, e40, 10.2337/dc16-2200 · DOI · Paper page
  27. Szalat, 2018, Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia, Drug Safety, 41, 239, 10.1007/s40264-017-0602-6 · DOI
  28. Desai, 2017, Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus, Diabetes Obes Metab, 19, 897, 10.1111/dom.12876 · DOI

Cited by

Metadata

Authors
Mayer, G. J., Wanner, C., Weir, M. R., Inzucchi, S. E., Koitka-Weber, A., Hantel, S., von Eynatten, M., Zinman, B., & Cherney, D. Z. I.
Venue
Kidney International
Publisher
Elsevier BV
Published
2019-08
Volume
96
Issue
2
Pages
489-504
ISSN
0085-2538 (ISSN-L)
OpenAlex
W2922787184
Cited by
103
References
12
FWCI
12.28
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • Boehringer Ingelheim
  • Canadian Institutes of Health Research
  • Eli Lilly and Company
  • University Health Network
  • Juvenile Diabetes Research Foundation Canada
  • University of Toronto
  • Novo Nordisk
  • AstraZeneca
  • AbbVie
  • Canadian Diabetes Association

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.